Company intelligence / Profile preview

FabRx

London, England, United Kingdomfabrx.co.uk ↗

Ownership: Private
Employees: ~10
Development stage: Commercial

Overview

FabRx has commercialized the world’s first GMP-ready pharmaceutical 3D printer series for fully personalized precision medicine manufacture. Their platforms are deployed globally in hospitals and research settings. No direct clinical trial results as a drug developer since they provide enabling technology rather than proprietary therapeutics.

Therapeutic areas: Other
Modalities: Device (pharmaceutical 3D printers)Small molecule (via personalized drug compounding)Biologic (potentially via compounding/printing technology)Medical device (drug-loaded devices)
Industry: Non-Drug Biotech

Drug pipeline

1 asset

paracetamol

Research

Partnerships

Collaborators include academic institutions such as University College London.Printers are installed worldwide at hospitals/pharmacies/universities/pharma companies.

Beyond the preview

Go deeper on FabRx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FabRx.

Explore the full profile